{"id":"atenolol-thiazide","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Sexual dysfunction"},{"rate":null,"effect":"Bradycardia"}]},"_chembl":{"chemblId":"CHEMBL24","moleculeType":"Small molecule","molecularWeight":"266.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atenolol, a selective beta-1 blocker, decreases heart rate and cardiac contractility, reducing blood pressure and myocardial oxygen demand. The thiazide component inhibits sodium reabsorption in the distal convoluted tubule, promoting diuresis and reducing blood volume. Together, these complementary mechanisms provide additive antihypertensive effects.","oneSentence":"Atenolol Thiazide is a combination drug that reduces blood pressure by blocking beta-adrenergic receptors (atenolol) and promoting sodium and water excretion through the kidneys (thiazide diuretic).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:19:19.411Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris"}]},"trialDetails":[{"nctId":"NCT00140959","phase":"PHASE4","title":"Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02-01","conditions":"Hypertension","enrollment":120},{"nctId":"NCT01646437","phase":"PHASE3","title":"The International Polycap Study 3 (TIPS-3)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2012-06","conditions":"Cardiovascular Disease, Fractures, Cancers","enrollment":7793},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT00535925","phase":"PHASE4","title":"Nephropathy In Type 2 Diabetes and Cardio-renal Events","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":"Diabetic Nephropathy","enrollment":850},{"nctId":"NCT00263393","phase":"PHASE4","title":"Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS)","status":"COMPLETED","sponsor":"The George Institute","startDate":"2005-12","conditions":"Myocardial Infarction, Angina Pectoris, Cerebrovascular Accidents","enrollment":3712},{"nctId":"NCT00246519","phase":"PHASE4","title":"Pharmacogenomic Evaluation of Antihypertensive Responses","status":"COMPLETED","sponsor":"University of Florida","startDate":"2005-10","conditions":"Hypertension","enrollment":1701},{"nctId":"NCT03147092","phase":"EARLY_PHASE1","title":"Matão Controlling Hypertension (MatCH Study): Rationale and Design","status":"UNKNOWN","sponsor":"Centro Neurológico de Pesquisa e Reabiitação, Brazil","startDate":"2018-02-01","conditions":"Hypertension, Blood Pressure","enrollment":15000},{"nctId":"NCT01748123","phase":"PHASE4","title":"EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2016-08","conditions":"Hypertension","enrollment":""},{"nctId":"NCT00438113","phase":"PHASE4","title":"Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF","status":"COMPLETED","sponsor":"Nova Scotia Health Authority","startDate":"2009-12","conditions":"Atrial Fibrillation","enrollment":184},{"nctId":"NCT00171132","phase":"PHASE4","title":"VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-08","conditions":"Hypertension","enrollment":64},{"nctId":"NCT00232882","phase":"PHASE4","title":"Pharmacodynamic Influences of Candesartan, Atenolol, Hydrochlorothiazide and Drug Combinations in Hypertensive Patients.","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2003-12","conditions":"Hypertension","enrollment":86},{"nctId":"NCT00661895","phase":"PHASE4","title":"Black Education and Treatment of Hypertension (BEAT HTN)","status":"COMPLETED","sponsor":"Creighton University","startDate":"2005-08","conditions":"Hypertension","enrollment":99},{"nctId":"NCT00133692","phase":"PHASE4","title":"INVEST: INternational VErapamil SR Trandolapril STudy","status":"COMPLETED","sponsor":"University of Florida","startDate":"1997-09","conditions":"Hypertension, Coronary Artery Disease","enrollment":22000},{"nctId":"NCT00396656","phase":"PHASE3","title":"Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-12","conditions":"Hypertension","enrollment":30},{"nctId":"NCT00443794","phase":"NA","title":"The Indian POLYCAP Study (TIPS)","status":"COMPLETED","sponsor":"St. John's Research Institute","startDate":"2007-03","conditions":"Cardiovascular Diseases","enrollment":2050},{"nctId":"NCT00813722","phase":"PHASE4","title":"Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"1999-03","conditions":"Blood Pressure","enrollment":400},{"nctId":"NCT00772499","phase":"PHASE4","title":"Vascular Improvement With Olmesartan Medoxomil Study","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2002-11","conditions":"Hypertension","enrollment":100},{"nctId":"NCT00185185","phase":"PHASE3","title":"Olmesartan Medoxomil in Atherosclerosis","status":"COMPLETED","sponsor":"Sankyo Pharma Gmbh","startDate":"2001-11","conditions":"Essential Hypertension, Atherosclerotic Cardiovascular Disease","enrollment":165}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Atenolol Thiazide","genericName":"Atenolol Thiazide","companyName":"Institut de Recherches Cliniques de Montreal","companyId":"institut-de-recherches-cliniques-de-montreal","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atenolol Thiazide is a combination drug that reduces blood pressure by blocking beta-adrenergic receptors (atenolol) and promoting sodium and water excretion through the kidneys (thiazide diuretic). Used for Hypertension, Angina pectoris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}